## Abstract Prolonged parenteral androgen therapy for 1 year resulted in the hypersecretion of prostate specific antigen (PSA) in a patient with no clinical evidence of prostatic carcinoma, who had been treated with diethylstilbestrol (DES) for 9 years. The PSA level declined to normal values upon
The effect of orgasm on prostate-specific antigen
โ Scribed by R. F. Kropman; W. Kieviet; R. C. M. Pelger; P. L. Venema
- Publisher
- Springer-Verlag
- Year
- 1994
- Tongue
- English
- Weight
- 264 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0724-4983
No coin nor oath required. For personal study only.
โฆ Synopsis
S u m m a r y . To identify the effect of orgasm on serum prostate-specific antigen (PSA) levels, a prospective trial before and after orgasm was performed in 14 healthy colleagues aged 3 2 -6 2 years (mean, 44.4 years) with no evidence of prostatic disease. P S A determinations were performed on serum samples obtained before and after orgasm. Significant changes in P S A levels after orgasm were found (P = 0.002, analysis of variance). We conclude that the impact of orgasm on P S A levels should be taken into account when the latter are used for the detection of prostatic disease.
๐ SIMILAR VOLUMES
Previous studies have suggested that serum prostate-specific antigen (PSA) levels are under androgenic influence, especially in patients with adenocarcinoma of the prostate. PSMA (prostate-specific membrane antigen) is thought to reflect hormonal or clonal resistance or an independence with respect
ated with higher pathologic stage and grade in patients undergoing radical prostatectomy (RP). In earlier studies, serum prostate specific membrane antigen (PSMA)
Background. Prostate specific antigen (PSA) is useful as a tumor marker for monitoring patients with prostate cancer after definitive therapy. Limitations have been noted when PSA was used for the early detection of prostate cancer. The use of prostate specific antigen density [PSAD = PSA (ng/ml)/pr
Prostate-specific antigen (PSA) is a wellcharacterized human prostate-specific glycoprotein. PSA has been shown to be the most effective immunohistologic marker for prostate cancer, as well as the most useful serologic test in staging and monitoring prostate cancer and in early detection of recurren